Sudarshan Pharma Industries is witnessing a remarkable surge in its stock price, climbing nearly 2% to ₹419 today, October 1st, after announcing a 1:10 stock split. The stock, approaching its all-time high of ₹434, has been on a bullish run over the last four months, soaring 552%. This performance has caught the attention of those looking to invest in stocks, particularly in the pharmaceutical sector.
Stock split announcement
The company recently approved a 1:10 stock split, wherein one equity share of ₹10 face value will be split into 10 shares of ₹1 face value each. This move is expected to increase liquidity and make the stock more accessible to retail investors who wish to invest in stocks. The stock split is subject to shareholder approval and is seen as a strategic step to boost investor interest and market participation.
Company expansions and acquisitions
Sudarshan Pharma has been aggressively expanding its business. It recently established a subsidiary, Sudarshan Maven Pharma, focusing on developing pharmaceutical ingredients and intermediates. Furthermore, the acquisition of a 100% stake in Ratna Lifesciences Pvt Ltd is a pivotal step for the company, allowing it to venture into oncology. Additionally, the company plans to acquire land in Maharashtra Industrial Development Corporation (MIDC) to enhance production capacity, particularly in the oncology sector, potentially increasing its annual turnover tenfold.
These expansions signal promising growth, making Sudarshan Pharma a favourable option for investors in pharmaceutical stocks.
Stellar performance of Sudarshan Pharma stock
Sudarshan Pharma’s shares have seen an impressive rise, jumping from ₹64.25 to ₹419 in just four months, reflecting a massive 552% increase. In September alone, the stock surged 123%, following a 20% gain in August and a 90% rise in July. This bullish trend has strengthened investor confidence, positioning Sudarshan Pharma as an attractive option for those wanting to invest in stocks.
Invest safely
With its recent stock split announcement and strategic expansions in the pharmaceutical sector, Sudarshan Pharma has positioned itself as a strong contender in the market. Investors seeking to invest in stocks should keep a close eye on the company’s ongoing developments, as its recent performance and upcoming stock split indicate potential for long-term growth.
For android only